<annotation text="Abstract Ranibizumab (Lucentis®), an inhibitor of multiple vascular endothelial growth factor A isoforms, is approved for the intravitreal treatment of neovascular (wet) age-related macular degeneration (AMD). In clinical trials in patients with neovascular AMD, monthly or less frequent injections of ranibizumab were effective in the treatment of predominantly classic choroidal neovascularization (CNV) and minimally classic or occult CNV lesions. Ranibizumab has a well-established safety profile, and is associated with low rates of ocular and systemic serious adverse events. In head-to-head comparisons, the efficacy of monthly bevacizumab was equivalent to monthly ranibizumab at 1 and 2 years, individualized treatment with bevacizumab was equivalent to individualized treatment with ranibizumab at 1 and 2 years, and bimonthly aflibercept was noninferior to monthly ranibizumab at 1 year. These trials were not powered to detect between-treatment differences in safety.">
  <surfaceForm name="profile" offset="493">
    <resource label="Offender profiling" uri="Offender_profiling" contextualScore="0.9736112344672866" percentageOfSecondRank="0.001649699159463509" support="219" priorScore="1.8216468642561826E-6" finalScore="0.9971346180258795" types=""/>
  </surfaceForm>
  <surfaceForm name="vascular endothelial growth factor A" offset="59">
    <resource label="Vascular endothelial growth factor A" uri="Vascular_endothelial_growth_factor_A" contextualScore="1.0" percentageOfSecondRank="0.0" support="25" priorScore="2.0795055528038615E-7" finalScore="1.0" types="DBpedia:Biomolecule, DBpedia:Protein"/>
  </surfaceForm>
  <surfaceForm name="These" offset="899">
    <resource label="E. H. Carr" uri="E._H._Carr" contextualScore="0.9942953402649141" percentageOfSecondRank="2.1212541828467916E-4" support="92" priorScore="7.65258043431821E-7" finalScore="0.9995765520324555" types="DBpedia:Agent, Schema:Person, Http://xmlns.com/foaf/0.1/Person, DBpedia:Person"/>
  </surfaceForm>
  <surfaceForm name="ranibizumab" offset="673">
    <resource label="Ranibizumab" uri="Ranibizumab" contextualScore="1.0" percentageOfSecondRank="0.0" support="40" priorScore="3.3272088844861784E-7" finalScore="1.0" types="DBpedia:Drug"/>
  </surfaceForm>
  <surfaceForm name="inhibitor" offset="37">
    <resource label="Enzyme inhibitor" uri="Enzyme_inhibitor" contextualScore="0.04866247509649287" percentageOfSecondRank="0.012933464723953058" support="1116" priorScore="9.282912787716438E-6" finalScore="0.978796925616436" types=""/>
  </surfaceForm>
  <surfaceForm name="patients" offset="232">
    <resource label="Patient" uri="Patient" contextualScore="0.9999999966413498" percentageOfSecondRank="1.920959701495018E-12" support="2793" priorScore="2.323223603592474E-5" finalScore="0.9999999999980673" types=""/>
  </surfaceForm>
  <surfaceForm name="In" offset="210">
    <resource label="Identity matrix" uri="Identity_matrix" contextualScore="0.8080312268415993" percentageOfSecondRank="0.00496279579826365" support="342" priorScore="2.844763596235682E-6" finalScore="0.42962115952797697" types=""/>
    <resource label="Indium" uri="Indium" contextualScore="0.16778661865443556" percentageOfSecondRank="0.7561752123436618" support="443" priorScore="3.6848838395684425E-6" finalScore="0.5681502811979579" types=""/>
  </surfaceForm>
  <surfaceForm name="AMD" offset="258">
    <resource label="Advanced Micro Devices" uri="Advanced_Micro_Devices" contextualScore="0.8534185598308791" percentageOfSecondRank="3.126682699623171E-5" support="2018" priorScore="1.6785768822232768E-5" finalScore="0.9999686186380634" types="DBpedia:Agent, Schema:Organization, DBpedia:Organisation, DBpedia:Company"/>
  </surfaceForm>
  <surfaceForm name="rates" offset="529">
    <resource label="Reaction rate" uri="Reaction_rate" contextualScore="0.1555952587428157" percentageOfSecondRank="0.022318530376534477" support="376" priorScore="3.1275763514170077E-6" finalScore="0.19525741365608298" types=""/>
    <resource label="Exchange rate" uri="Exchange_rate" contextualScore="0.8328785151851503" percentageOfSecondRank="0.2449039931993705" support="1262" priorScore="1.0497344030553892E-5" finalScore="0.7972814616261833" types=""/>
  </surfaceForm>
  <surfaceForm name="ranibizumab" offset="793">
    <resource label="Ranibizumab" uri="Ranibizumab" contextualScore="1.0" percentageOfSecondRank="0.0" support="40" priorScore="3.3272088844861784E-7" finalScore="1.0" types="DBpedia:Drug"/>
  </surfaceForm>
  <surfaceForm name="systemic" offset="549">
    <resource label="Route of administration" uri="Route_of_administration" contextualScore="0.9999655413810552" percentageOfSecondRank="3.0529952296472797E-5" support="309" priorScore="2.5702688632655728E-6" finalScore="0.9999692838250177" types=""/>
  </surfaceForm>
  <surfaceForm name="classic" offset="420">
    <resource label="British Classic Races" uri="British_Classic_Races" contextualScore="0.031572098174588" percentageOfSecondRank="0.08211304839906253" support="977" priorScore="8.12670770035749E-6" finalScore="0.43859844323434527" types=""/>
    <resource label="Classical antiquity" uri="Classical_antiquity" contextualScore="0.6495357591125784" percentageOfSecondRank="0.9325372695229653" support="2368" priorScore="1.9697076596158176E-5" finalScore="0.4703280582648542" types=""/>
  </surfaceForm>
  <surfaceForm name="safety" offset="972">
    <resource label="Safety" uri="Safety" contextualScore="0.998976038102812" percentageOfSecondRank="3.811867833738541E-6" support="1198" priorScore="9.964990609036104E-6" finalScore="0.9999943704896601" types=""/>
  </surfaceForm>
  <surfaceForm name="occult" offset="431">
    <resource label="Occult" uri="Occult" contextualScore="0.010579008064148514" percentageOfSecondRank="0.07393517569503401" support="1935" priorScore="1.6095372978701886E-5" finalScore="0.9302717755904916" types=""/>
  </surfaceForm>
  <surfaceForm name="Abstract" offset="0">
    <resource label="Abstraction" uri="Abstraction" contextualScore="0.020346289612164656" percentageOfSecondRank="0.08893327879275784" support="626" priorScore="5.207081904220869E-6" finalScore="0.10436050093794152" types=""/>
    <resource label="Abstract art" uri="Abstract_art" contextualScore="0.002420468858222969" percentageOfSecondRank="0.3526884461733631" support="1865" priorScore="1.5513111423916808E-5" finalScore="0.29589997083897496" types=""/>
    <resource label="Abstract (summary)" uri="Abstract_(summary)" contextualScore="0.9638997512143974" percentageOfSecondRank="0.5062962778698615" support="222" priorScore="1.8466009308898289E-6" finalScore="0.5844403440687216" types=""/>
  </surfaceForm>
  <surfaceForm name="adverse events" offset="566">
    <resource label="Adverse effect" uri="Adverse_effect" contextualScore="0.99754540339074" percentageOfSecondRank="5.888681130318801E-5" support="887" priorScore="7.3780857013481E-6" finalScore="0.9999411166561137" types="DBpedia:Disease"/>
  </surfaceForm>
  <surfaceForm name="In" offset="582">
    <resource label="Identity matrix" uri="Identity_matrix" contextualScore="0.8080312268415993" percentageOfSecondRank="0.00496279579826365" support="342" priorScore="2.844763596235682E-6" finalScore="0.42962115952797697" types=""/>
    <resource label="Indium" uri="Indium" contextualScore="0.16778661865443556" percentageOfSecondRank="0.7561752123436618" support="443" priorScore="3.6848838395684425E-6" finalScore="0.5681502811979579" types=""/>
  </surfaceForm>
  <surfaceForm name="efficacy" offset="615">
    <resource label="Efficacy" uri="Efficacy" contextualScore="0.9999999999989768" percentageOfSecondRank="6.570013120289524E-15" support="536" priorScore="4.458459905211479E-6" finalScore="1.0" types=""/>
  </surfaceForm>
  <surfaceForm name="powered" offset="921">
    <resource label="Statistical power" uri="Statistical_power" contextualScore="0.9987105900730519" percentageOfSecondRank="0.013264592628946248" support="196" priorScore="1.6303323533982273E-6" finalScore="0.9868898377752267" types=""/>
  </surfaceForm>
  <surfaceForm name="safety" offset="486">
    <resource label="Safety" uri="Safety" contextualScore="0.998976038102812" percentageOfSecondRank="3.811867833738541E-6" support="1198" priorScore="9.964990609036104E-6" finalScore="0.9999943704896601" types=""/>
  </surfaceForm>
  <surfaceForm name="bevacizumab" offset="733">
    <resource label="Bevacizumab" uri="Bevacizumab" contextualScore="1.0" percentageOfSecondRank="0.0" support="112" priorScore="9.316184876561299E-7" finalScore="1.0" types="DBpedia:Drug"/>
  </surfaceForm>
  <surfaceForm name="Ranibizumab" offset="9">
    <resource label="Ranibizumab" uri="Ranibizumab" contextualScore="1.0" percentageOfSecondRank="0.0" support="40" priorScore="3.3272088844861784E-7" finalScore="1.0" types="DBpedia:Drug"/>
  </surfaceForm>
  <surfaceForm name="isoforms" offset="96">
    <resource label="Protein isoform" uri="Protein_isoform" contextualScore="0.9048968237361769" percentageOfSecondRank="8.513260921335421E-5" support="733" priorScore="6.097110280820922E-6" finalScore="0.9998944911652643" types=""/>
  </surfaceForm>
  <surfaceForm name="ocular" offset="538">
    <resource label="Human eye" uri="Human_eye" contextualScore="0.9999999955099383" percentageOfSecondRank="7.23380410336449E-11" support="3092" priorScore="2.5719324677078157E-5" finalScore="0.9999999999101874" types="DBpedia:AnatomicalStructure"/>
  </surfaceForm>
  <surfaceForm name="classic" offset="363">
    <resource label="British Classic Races" uri="British_Classic_Races" contextualScore="0.031572098174588" percentageOfSecondRank="0.08211304839906253" support="977" priorScore="8.12670770035749E-6" finalScore="0.43859844323434527" types=""/>
    <resource label="Classical antiquity" uri="Classical_antiquity" contextualScore="0.6495357591125784" percentageOfSecondRank="0.9325372695229653" support="2368" priorScore="1.9697076596158176E-5" finalScore="0.4703280582648542" types=""/>
  </surfaceForm>
  <surfaceForm name="wet" offset="165">
    <resource label="Water" uri="Water" contextualScore="0.480884347158098" percentageOfSecondRank="0.09473901912363965" support="23703" priorScore="1.9716208047243971E-4" finalScore="0.862094792782233" types=""/>
  </surfaceForm>
  <surfaceForm name="age-related macular degeneration" offset="170">
    <resource label="Macular degeneration" uri="Macular_degeneration" contextualScore="1.0" percentageOfSecondRank="0.0" support="411" priorScore="3.418707128809548E-6" finalScore="1.0" types="DBpedia:Disease"/>
  </surfaceForm>
  <surfaceForm name="ranibizumab" offset="302">
    <resource label="Ranibizumab" uri="Ranibizumab" contextualScore="1.0" percentageOfSecondRank="0.0" support="40" priorScore="3.3272088844861784E-7" finalScore="1.0" types="DBpedia:Drug"/>
  </surfaceForm>
  <surfaceForm name="bevacizumab" offset="635">
    <resource label="Bevacizumab" uri="Bevacizumab" contextualScore="1.0" percentageOfSecondRank="0.0" support="112" priorScore="9.316184876561299E-7" finalScore="1.0" types="DBpedia:Drug"/>
  </surfaceForm>
  <surfaceForm name="approved" offset="109">
    <resource label="Food and Drug Administration" uri="Food_and_Drug_Administration" contextualScore="0.9999999998789235" percentageOfSecondRank="1.7750410844719819E-12" support="4822" priorScore="4.010950310248088E-5" finalScore="0.999999999998181" types="DBpedia:Agent, Schema:Organization, DBpedia:Organisation, Schema:GovernmentOrganization, DBpedia:GovernmentAgency"/>
  </surfaceForm>
  <surfaceForm name="multiple" offset="50">
    <resource label="Multiple (mathematics)" uri="Multiple_(mathematics)" contextualScore="0.7230510544359382" percentageOfSecondRank="0.05344399236819246" support="71" priorScore="5.905795769962966E-7" finalScore="0.9344323443588118" types=""/>
  </surfaceForm>
  <surfaceForm name="minimally" offset="410">
    <resource label="Minimalism" uri="Minimalism" contextualScore="0.9587243396418507" percentageOfSecondRank="0.008742753391801087" support="1236" priorScore="1.0281075453062291E-5" finalScore="0.99133301865285" types=""/>
  </surfaceForm>
  <surfaceForm name="Lucentis" offset="22">
    <resource label="Ranibizumab" uri="Ranibizumab" contextualScore="1.0" percentageOfSecondRank="0.0" support="40" priorScore="3.3272088844861784E-7" finalScore="1.0" types="DBpedia:Drug"/>
  </surfaceForm>
  <surfaceForm name="AMD" offset="204">
    <resource label="Advanced Micro Devices" uri="Advanced_Micro_Devices" contextualScore="0.8534185598308791" percentageOfSecondRank="3.126682699623171E-5" support="2018" priorScore="1.6785768822232768E-5" finalScore="0.9999686186380634" types="DBpedia:Agent, Schema:Organization, DBpedia:Organisation, DBpedia:Company"/>
  </surfaceForm>
  <surfaceForm name="frequent" offset="279">
    <resource label="Frequentative" uri="Frequentative" contextualScore="0.9999467867042076" percentageOfSecondRank="0.0" support="63" priorScore="5.24035399306573E-7" finalScore="0.9999991005581202" types=""/>
  </surfaceForm>
  <surfaceForm name="ranibizumab" offset="876">
    <resource label="Ranibizumab" uri="Ranibizumab" contextualScore="1.0" percentageOfSecondRank="0.0" support="40" priorScore="3.3272088844861784E-7" finalScore="1.0" types="DBpedia:Drug"/>
  </surfaceForm>
  <surfaceForm name="injections" offset="288">
    <resource label="Injection (medicine)" uri="Injection_(medicine)" contextualScore="0.9999999869211252" percentageOfSecondRank="1.9590960634517964E-9" support="361" priorScore="3.002806018248776E-6" finalScore="0.9999999980408347" types=""/>
  </surfaceForm>
  <surfaceForm name="CNV" offset="438">
    <resource label="Copy-number variation" uri="Copy-number_variation" contextualScore="0.9999999999840838" percentageOfSecondRank="1.6610333778416234E-11" support="132" priorScore="1.097978931880439E-6" finalScore="0.9999999999834017" types=""/>
  </surfaceForm>
  <surfaceForm name="CNV" offset="401">
    <resource label="Copy-number variation" uri="Copy-number_variation" contextualScore="0.9999999999840838" percentageOfSecondRank="1.6610333778416234E-11" support="132" priorScore="1.097978931880439E-6" finalScore="0.9999999999834017" types=""/>
  </surfaceForm>
  <surfaceForm name="Ranibizumab" offset="451">
    <resource label="Ranibizumab" uri="Ranibizumab" contextualScore="1.0" percentageOfSecondRank="0.0" support="40" priorScore="3.3272088844861784E-7" finalScore="1.0" types="DBpedia:Drug"/>
  </surfaceForm>
  <surfaceForm name="lesions" offset="442">
    <resource label="Lesion" uri="Lesion" contextualScore="0.9999999382647521" percentageOfSecondRank="2.899288745280804E-10" support="1500" priorScore="1.2477033316823168E-5" finalScore="0.9999999997100986" types=""/>
  </surfaceForm>
  <surfaceForm name="clinical trials" offset="213">
    <resource label="Clinical trial" uri="Clinical_trial" contextualScore="0.9999999615430405" percentageOfSecondRank="1.142071778829483E-11" support="2041" priorScore="1.6977083333090723E-5" finalScore="0.9999999999886313" types=""/>
  </surfaceForm>
  <surfaceForm name="detect" offset="932">
    <resource label="Screening (medicine)" uri="Screening_(medicine)" contextualScore="0.9999998367191116" percentageOfSecondRank="1.2209888912668543E-7" support="618" priorScore="5.1405377265311456E-6" finalScore="0.9999997251575601" types=""/>
  </surfaceForm>
  <surfaceForm name="differences" offset="957">
    <resource label="Sexual dimorphism" uri="Sexual_dimorphism" contextualScore="0.04531375500696071" percentageOfSecondRank="0.15865461810604858" support="1925" priorScore="1.6012192756589734E-5" finalScore="0.19402251671230586" types=""/>
    <resource label="Complement (set theory)" uri="Complement_(set_theory)" contextualScore="0.7845728974286088" percentageOfSecondRank="0.26098640513553445" support="426" priorScore="3.5434774619777796E-6" finalScore="0.7434200130522003" types=""/>
  </surfaceForm>
</annotation>